Anxiety disorders associated with chemotherapy for breast cancer
Conditions
Interventions
Post-operative breast cancer group:(surgical) operation
Breast Cancer Chemotherapy-Related Anxiety Disorder Group:Basic treatment plan: standardized chemotherapy plan (based on the 2023 Chinese Society of Clinical Oncology Breast Cancer Diagnosis and Treat
Breast Cancer Chemotherapy-Related Anxiety Disorder Herbal Intervention Group:Basic Treatment Plan + Fuxia Dihuang Tang
Sponsors
Xiamen Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Female, aged 18-75 years (both 18 and 75 years); (2) Stage I-IIIA breast cancer patients with a clear pathologic diagnosis who received surgical treatment and postoperative chemotherapy; (3) The chemotherapy regimen was the EC regimen (epirubicin + cyclophosphamide); (4) KPS =60 and expected survival =1 year; (5) Patients who received chemotherapy for the first time and entered the maintenance phase with more than stable disease as evaluated by efficacy after 2 cycles of chemotherapy; (6) Patients with anxiety states, 14 points = Hamilton Anxiety Scale (HAMA) < 29 points; (7) Have some ability to understand and express themselves, participate in this study voluntarily, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Use of antibiotics, probiotics or prebiotics as medications or supplements, laxatives, antispasmodics, and antidiarrheals (e.g., orlistat, lactulose), etc., 4 weeks prior to enrollment and during the study period; (2) Combination of amoebic dysentery, chronic inflammatory diseases of the intestinal tract, etc; (3) Acute gastroenteritis within the last 1 week; (4) Accompanied by severe liver disease, kidney disease, autoimmune disease, infectious disease, etc; (5) Smoking, drinking and other bad habits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resting-state functional magnetic resonance index;Indicators of intestinal flora;Indicators of intestinal metabolites; | — |
Secondary
| Measure | Time frame |
|---|---|
| Whole Blood Transcriptomics Indicators; | — |
Countries
China
Contacts
Public ContactXiao-hua Pei
Xiamen Hospital of Traditional Chinese Medicine
Outcome results
None listed